Stock Analysis

The company's preliminary final report sets out revenue from continuing operations for the year ended 30 June 2026, with the company stating that revenue increased 238%. The report includes a statement of profit or loss, a statement of financial position and the remuneration report. …

StepChange reported unaudited revenue of A$16.8 million for the quarter, up 34% on the prior corresponding period, and underlying EBITDA of A$1.40 million, up 44%. The company said both increases came from organic growth across the existingBusinessand the contribution of the Broadreach Group, which …

Adherium reported remote patient monitoring subscription accrual revenue of A$539,000, up 12.5% on the prior quarter and the fifth consecutive quarter of record revenue in that category. Customer cash receipts were A$544,000, up 33% quarter on quarter, including a A$257,917Cash Receiptfrom the AstraZeneca Arrival …

Atomo reportedRevenueof A$1.63 million for the quarter ended 30 September 2026, which the company said was growth of 140% over the comparable quarter in 2026. FebriDx orders were A$680,000 for the quarter, up 314% year on year. Cash receipts were A$2.51 million, including A$2.40 …

Cynata said it raised approximately A$912,962 before costs from its fully underwritten pro-rata renounceable entitlement offer, which followed an announcement dated 30 October 2026. The underwriter, Caravel Securities, also advised that firm commitments had been received for a placement of approximately 55 million new …

Epsilon reported quarterly receipts of A$3.9 million for the September 2026 quarter, up 34% year on year. Year-to-date revenue reached A$11.5 million, which the company said is tracking at A$16 million annualised and up 80%. Epsilon Pharmacy, established about 12 months earlier, is now …

Patrys said the first participants were dosed in its RLS-2202 Phase 1a trial at CMAX, following Human Research Ethics Committee approval. All four Cohort 1 participants completed dosing, follow-up and planned clinical assessments. After quarter end, the Safety Review Committee found the cohort had …